US Bancorp’s SpyGlass Pharma SGP Stock Holding History

US Bancorp’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.18K	Buy	+84	New	+$2.07K	﹤0.01%	3909

Other funds holding SGP

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Virtus Investment Advisers Hartford, Connecticut $453M AUM 48.99% 1-Year Est. Return

US Bancorp's SGP Position: Q3 2026 in Review

US Bancorp opened a new position in SpyGlass Pharma (SGP) in Q3 2026: 84 shares worth $2.18K. The stake represents ﹤0.01% of the portfolio and ranks #3909 among its holdings.

34 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

US Bancorp held 84 shares of SpyGlass Pharma worth $2.18K as of Q3 2026.
SpyGlass Pharma was a new US Bancorp position in Q3 2026.
SpyGlass Pharma made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #3909 holding.
34 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.